title: Mirabegron - a selective β3-adrenoreceptor agonist for the treatment of overactive bladder.
abstract: Overactive bladder is a common condition that significantly impacts overall quality of life. Antimuscarinics are the current main pharmacological option for treatment; however, many patients fail to adhere to therapy due to troublesome side effects. Mirabegron is a new beta-3 adrenoreceptor agonist which causes detrusor smooth muscle relaxation and has been proposed to be effective for treating overactive bladder symptoms. Mirabegron has been shown to be superior to placebo for reducing the mean number of incontinence episodes per 24 hours and the mean number of micturitions per 24 hours. Side effects such as dry mouth were observed at similar or lower rates than those seen for placebo and antimuscarinics. Higher doses of mirabegron were associated with minor increases in pulse rate and mean blood pressure. Mirabegron offers a new alternative for treating overactive bladder in patients for which antimuscarinics are either not tolerated or not appropriate.
authors.affiliation: Department of Urogynaecology, St Mary's Hospital, London, United Kingdom.
authors.forename: Alka A
authors.initials: AA
authors.lastname: Bhide
authors.forename: G Alessandro
authors.initials: GA
authors.lastname: Digesu
authors.forename: Ruwan
authors.initials: R
authors.lastname: Fernando
authors.forename: Vik
authors.initials: V
authors.lastname: Khullar
keywords: beta-3 adrenoreceptor agonist; mirabegron; overactive bladder